[LCID Study Number: 2018-019]
Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma
The primary objective of this study is to compare the complete response rate at 6 cycles after randomization, defined by centrally read PET/CT scans of 2 targeted therapeutic regimens (obinutuzumab + TGR-1202 or obinutuzumab + lenalidomide) with obinutuzumab + chemotherapy in patients with early relapsing or refractory follicular lymphoma.
Primary Contact Email: [email protected]
Primary Contact Phone: 781-744-2734